On this page

Albac® 50 Type A Medicated Article

Bacitracin Zinc

Veterinary ANADA Approved 2 applications 1 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Albac® 50 Type A Medicated Article
Active ingredient
Bacitracin Zinc
Application type
ANADA
Sponsor
Zoetis Inc.
Applications on record
2
First published
June 1, 2016

Applications

Source: Animal Drugs @ FDA
Every Green Book application recorded for this proprietary name.
Application no. Type Status Withdrawn
200223 ANADA Approved —
98452 NADA Approved —

Adverse event reports

Source: openFDA VeDDRA
1
Reports mentioning this ingredient
January 13, 2020 – January 13, 2020
1
Classified serious
per reporter assessment
0
Lack of expected efficacy
resistance signal
0
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “BACITRACIN ZINC”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Species affected

Source: openFDA VeDDRA
Cat 1

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient